^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Nplate (romiplostim)

    i
    Other names: AMG531, AMG 531, AMG-531
    Associations

    News

    Trials
    Company:
    Amgen, Kyowa Kirin
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    Associations

    News

    Trials
    4d
    Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation-Induced Premature Aging. (PubMed, Pharmacol Res Perspect)
    Although bone marrow cell recovery was incomplete, spleen cell counts were significantly restored (2-fold) by 50 μg/kg RP, and SA-β-gal activity, a marker of cellular senescence, was also significantly suppressed by approximately 15%. These findings suggest that RP may partially ameliorate radiation-induced premature aging, providing a basis for future research addressing health issues associated with aging and radiation exposure.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    Nplate (romiplostim)
    1m
    A Multicenter, Prospective, Observational Study of Romiplostim N01 in Combination with Immunosuppressive Therapy (IST) for the Treatment of Aplastic Anemia (AA) (ChiCTR2500111349)
    P4, N=40, Not yet recruiting, The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University
    New P4 trial
    |
    Nplate (romiplostim)
    1m
    Prospective, Single-Arm, Multicenter Clinical Study of Romiplostim N01 for the Treatment of Thrombocytopenia Induced by Concurrent Chemoradiotherapy in Solid Tumors (ChiCTR2500110699)
    P4, N=92, Not yet recruiting, Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University
    New P4 trial
    |
    Nplate (romiplostim)
    1m
    Study on the Efficacy and Safety of Romiplostim Injection N01 as Second-line Treatment for Thrombocytopenia Following Hematologic Malignancy Therapy (ChiCTR2500109111)
    P4, N=30, Not yet recruiting, First Affiliated Hospital of Kunming Medical University; First Affiliated Hospital of Kunming Medical University
    New P4 trial
    |
    Nplate (romiplostim)
    1m
    The Efficacy and Safety of Cyclosporine plus Romiplostim N01:  A Prospective, Single-Arm, Open-Label Phase II Clinical Study (ChiCTR2500109038)
    P4, N=32, Not yet recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P4 trial
    |
    Nplate (romiplostim)
    2ms
    Case Report: Life-threatening cisplatin-induced myelosuppression in pediatric osteosarcoma: molecular mechanisms, pharmacogenomic profiling, and targeted clinical management. (PubMed, Front Pharmacol)
    Targeted interventions (G-CSF, romiplostim, meropenem) led to hematological recovery within 14 days. This case implicates cisplatin overdose with impaired metabolic clearance as the primary toxicity mechanism.
    Journal
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    cisplatin • Nplate (romiplostim)
    2ms
    Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Assiut University
    New trial
    |
    Nplate (romiplostim)
    2ms
    Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    Rituxan (rituximab) • Nplate (romiplostim)
    3ms
    Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Kyowa Kirin Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    Nplate (romiplostim)
    3ms
    Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=68, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    Nplate (romiplostim)
    3ms
    Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Nplate (romiplostim)
    4ms
    Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Zhujiang Hospital
    New P2 trial
    |
    Nplate (romiplostim)